Concepedia

Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen, Lars Kristian Munck, Jan Fallingborg, Lisbet Ambrosius Christensen, Gitte Pedersen, Jens Kjeldsen, Bent Ascanius Jacobsen, Anne Sophie Oxholm,

Digestive Diseases and Sciences · 2015 · 78 citations · 13 references

DOI

Concepts

References

13

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

Gert Van Assche, James O. Lindsay, Marc Lémann et al. · Journal of Crohn s and Colitis · 2010 · 1.5K citations

, , +11

Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial

Stephan R. Targan, Brian G. Feagan, Richard N. Fedorak et al. · Gastroenterology · 2007 · 614 citations

, , +8

Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease

Waqqas Afif, Edward V. Loftus, William A. Faubion et al. · The American Journal of Gastroenterology · 2010 · 487 citations · Full text

, , +17

Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial

Casper Steenholdt, Jørn Brynskov, Ole Østergaard Thomsen et al. · Gut · 2013 · 454 citations

, , +17

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

Matthieu Allez, Konstantinos Κarmiris, Édouard Louis et al. · Journal of Crohn s and Colitis · 2010 · 337 citations · Full text

, , +15